In colorectal cancer patients with BRAF mutation, double therapy (encorafenib 200 mg/day + cetuximab) and triple therapy (encorafenib 200 mg/day + alpelisib 300 mg/day + cetuximab) showed good clinical efficacy and safety. The gene discussed is BRAF; the disease is colorectal cancer.